Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.06 is 308% above its 5-year average of -0.03, near the high end of its 5-year range (-0.18–0.06).
As of the fiscal period ended Tuesday, June 30, 2026. 70.98% above its 12-month average of 0.04.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.06.
DEBT TO EQUITY RATIO
0.06
DEBT TO EQUITY RATIO AVG TTM
0.04
DEBT TO EQUITY RATIO AVG 3Y
-0.04
DEBT TO EQUITY RATIO AVG 5Y
-0.03
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+70.98%
CURRENT VS 3Y AVG
+277.45%
CURRENT VS 5Y AVG
+307.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 689 covered companies
CURRENT VS SECTOR MEDIAN
-41.01%
vs the sector median at left
Market Cap
$1.38M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$1.44M
Debt to Equity Ratio
0.24
TTM Avg
0.63
3Y Avg
2.77
5Y Avg
1.75
Market Cap
$1.25M
Debt to Equity Ratio
N/A
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$1.46M
Debt to Equity Ratio
0.02
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49M
Debt to Equity Ratio
0.83
TTM Avg
0.17
3Y Avg
0.16
5Y Avg
0.13
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewcelX Ltd. (NCEL) | $1.35M | 0.06 | 0.04 | -0.04 | -0.03 |
| Genprex, Inc. (GNPX)vs › | $1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.38M | 0.01 | 0.02 | 0.01 | 0.01 |
| INVO Fertility, Inc. (IVF)vs › | $1.44M | 0.24 | 0.63 | 2.77 | 1.75 |
| NEXGEL, Inc. (NXGL)vs › | $1.44M | 1.51 | 0.59 | 0.51 | 3.40 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.25M | N/A | 0.05 | 0.05 | 0.05 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.46M | 0.02 | N/A | N/A | N/A |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | 0.83 | 0.17 | 0.16 | 0.13 |
| Curis, Inc. (CRIS)vs › | $1.50M | 0.22 | 0.30 | 0.17 | 0.13 |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.14M | 0.05 | 0.07 | 0.07 | 0.07 |
Debt/Equity
0.06
Current Ratio
0.32
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.06 |
| 2025-12-31 | 0.05 |
| 2025-06-30 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-06-30 | -0.18 |
| 2023-12-31 | -0.18 |
| 2023-06-30 | 0.00 |
| 2022-12-31 | 0.00 |
| 2022-06-30 | -0.09 |
| 2021-12-31 | 0.00 |
| 2021-06-30 | 0.00 |
| 2020-12-31 | -0.23 |
| 2020-06-30 | -0.19 |
| 2019-12-31 | -0.14 |
| 2019-06-30 | -0.16 |
| 2018-12-31 | -0.80 |
| 2018-06-30 | 0.00 |
| 2017-12-31 | -1.15 |
| 2017-06-30 | 0.00 |
